Indication intelligence, analysis and sector perception

Verve Therapeutics (VERV -$8.02 or -19.08% to $23.27) crashes after FDA halts IND to test gene editor Ion patients

November 7, 2022 10:01am

VERVE-101 Investigational New Drug Application (IND) placed on HOLD by U.S. FDA

Verve submitted its IND application for VERVE-101 to the FDA in October and received notification of a hold from the FDA on Friday, 11/4/22. VERV expects to receive an official letter with the FDA’s questions within 30 days.

However, dosing was completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in patients with HeFH; Independent Data Safety Monitoring Board Recommended Proceeding to Second Dose Level in New Zealand and U.K.

The independent Data Safety Monitoring Board (DSMB) has reviewed safety data from the first cohort and recommended dose escalation to the planned second dose level, which is expected to begin soon.

The Bottom Line: NOT a good omen for gene editing companies as the …

FDA has placed a hold on its IND application to conduct a clinical trial evaluating VERVE-101 in patients with heterozygous familial hypercholesterolemia (HeFH), a prevalent and potentially life-threatening subtype of atherosclerotic cardiovascular disease (ASCVD), high cholesterol in the United States.

VERV has already begun human tests in New Zealand and the U.K., says it will likely receive the FDA's questions within a month.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.